Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 24 of the 199 sources its claims cite were checked for support.
Abstract
Chronic glucocorticoid (GC) treatment represents a widely-prescribed therapy for several diseases in consideration of both anti-inflammatory and immunosuppressive activity but, if used at high doses for prolonged periods, it can determine the systemic effects characteristic of Cushing’s syndrome. In addition to signs and symptoms of hypercortisolism, patients on chronic GC therapy are at risk to develop tertiary adrenal insufficiency after the reduction or the withdrawal of corticosteroids or during acute stress. This effect is mediated by the negative feedback loop on the hypothalamus-pituitary-adrenal (HPA) axis, which mainly involves corticotropin-release hormone (CRH), which represents the most important driver of adrenocorticotropic hormone (ACTH) release. In fact, after withdrawal of chronic GC treatment, reactivation of CRH secretion is a necessary prerequisite for the recovery of the HPA axis. In addition to the well-known factors which regulate the degree of inhibition of the HPA during synthetic GC therapy (type of compound, method of administration, cumulative dose, duration of the treatment, concomitant drugs which can increase the bioavailability of GCs), there is a considerable variation in individual physiology, probably related to different genetic profiles which regulate GC receptor activity. This may represent an interesting basis for possible future research fields.
Overview
CoChat Summary
TL;DR
Chronic synthetic glucocorticoid therapy can suppress the hypothalamus-pituitary-adrenal (HPA) axis and cause tertiary adrenal insufficiency, especially after dose reduction or withdrawal. Risk is shaped by compound, route, dose, duration, drug interactions, and individual genetic variation, while incidence estimates remain uncertain because diagnostic criteria vary.
Key findings
- Chronic glucocorticoids inhibit CRH and ACTH; after withdrawal, reactivation of CRH secretion is a necessary prerequisite for HPA axis recovery. A cited systematic review found hypoadrenalism persisted in 15% of patients retested three years after glucocorticoid withdrawal.
- Exposure is common: in 2008 almost 1% of the UK adult population were exposed to oral glucocorticoids, including 0.79% on long-term courses longer than three months. About 6% of hospitalized patients may have glucocorticoid-induced adrenal insufficiency, and prevalence estimates from large observational studies range from 14–63%.
- Adrenal crisis incidence was reported as 15.1/100 patient-years in tertiary adrenal insufficiency, compared with 5.2/100 patient-years in primary and 3.6/100 patient-years in secondary adrenal insufficiency. Infections were the most important precipitant, and about 30% of tertiary adrenal insufficiency crises occurred after glucocorticoid dose reduction.
- Risk predictors include prednisone >20 mg/day for >3 weeks making HPA suppression “likely,” evening/bedtime prednisone ≥5 mg for more than a few weeks also increasing risk, and 10–20 mg/day for >3 weeks being intermediate risk. Hydrocortisone and cortisone acetate are least suppressive; dexamethasone is the most potent ACTH suppressor.
Methods
- Narrative review evaluating the physiopathology and clinical effects of synthetic glucocorticoids on HPA function.
- Synthesizes literature on normal HPA physiology, synthetic glucocorticoid pharmacology, receptor biology, clinical adrenal insufficiency, and genetic variability, including cited systematic reviews, observational studies, animal models, and in vitro assays.
- No primary data collection or systematic search strategy is reported.
Limitations
- The paper states that a clear incidence of glucocorticoid-induced adrenal insufficiency cannot be assessed because of substantial differences in diagnostic criteria and variability in tests, including standard- and low-dose ACTH tests, insulin tolerance tests, and CRH stimulation, with different cut-offs and sensitivity/specificity.
- The paper notes that in vitro receptor transactivation systems differ from in vivo conditions, including steroid-metabolizing enzymes and heat shock protein concentrations, and that the literature on rapid glucocorticoid feedback is confusing and limited by not considering endogenous cortisol pulses.
- Evident from the text: as a narrative review, it does not describe a systematic search or formal quality appraisal, and many clinical estimates rely on heterogeneous cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Daily cortisol rhythm in healthy volunteers [23].](https://figures.cochat.ai/paper-figures/92ea4fe5961f4d21bab3c5ba7f3fae55/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-1.jpg)
![Figure 2 Corticotropin-release hormone (CRH) knock-out (KO) mouse model in regulation of hypothalamus-pituitary-adrenal (HPA) axis [59]. In CRH KO models proopiomelanocortin (POMC) mRNA, but not plasmatic adrenocorticotropic hormone (ACTH), rises after adrenalectomy. Glucocorticoids, but not mineralocorticoids (blue dotted arrow) reduce POMC increase induced by adrenalectomy. CRH administration restores a significant ACTH secretion.](https://figures.cochat.ai/paper-figures/3b5ea56302d54169a79ca7a76715b45c/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-2.jpg)
![Figure 3 Tissue side effects of synthetic glucocorticoids [1].](https://figures.cochat.ai/paper-figures/eacadeabe8df4e1faa6debafaceafd95/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-3.jpg)
Verification
Claims the paper makes
24 Valid · 2 Not valid · 161 Not checked · 24 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 1. Introduction
What the sources say
- Not checked yetcites [8] Schacke H. Docke W.D. Asadullah K. Mechanisms involved in the side effects of glucocorticoids Pharmacol. Ther. 2002 96 23 43 10.1016/S0163-7258(02)00297-8 12441176 source
- Supportedcites [9] Dibas A. Yorio T. Glucocorticoid therapy and ocular hypertension Eur. J. Pharmacol. 2016 787 57 71 10.1016/j.ejphar.2016.06.018 27388141 PMC5014726 source
The citation [9] is attached specifically to the 'ocular hypertension' element of the citing sentence (the systemic side-effect list is credited to [8]). Our copy supports that attribution directly: the Introduction (Section 1) states that chronic GC use is associated with deleterious side effects including glaucoma/cataracts, Section 6 ('Mechanism of steroid-induced secondary ocular hypertension') documents GC-induced IOP elevation occurring within hours, weeks (topical) or years (systemic), and the Conclusion (Section 10) affirms that 'the side effect of increasing intraocular pressure remains a great risk to develop glaucoma'. No contrary statement was found; the other listed effects (abdominal obesity, acne, infection, systemic hypertension) are not attributed to this source, so they do not weaken the verdict. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, novel treatments aimed at improving the benefit/risk ratio of GCs therapy (selective GC receptor agonists, SEGRAs), which are currently being trialed, are unlikely to alter the risk of adrenal insufficiency.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Partly supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 sourceExperimental — accuracy not yet measured
The Results report that the SEGRA ZK 216348 suppressed ACTH in rats about as effectively as prednisolone. The Discussion says the authors do not expect this compound class to have an advantage over standard glucocorticoids in suppressing the hypothalamo-pituitary-adrenal axis. The paper does not measure adrenal insufficiency risk in patients and says clinical studies are needed to determine whether its findings translate to humans. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This is probably because adrenal insufficiency can develop with the same mechanism, mediating the “therapeutic” anti-inflammatory effects of these compounds [36].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 source
The Abstract/Introduction of our copy states that 'the antiinflammatory effects are mediated to a major extent via transrepression' while 'a key mechanism for suppression of the hypothalamo-pituitary-adrenal axis, the decreased release of adrenocorticotropic hormone (ACTH) by corticotrophin-releasing hormone, is mediated by the GR via a transrepression mechanism.' The Discussion (and Abstract) confirm this consequence: the SEGRA ZK 216348 retained HPA-axis/ACTH suppression comparable to prednisolone precisely because that side effect shares the transrepression mechanism of the therapeutic effect. The paper phrases the outcome as HPA-axis/ACTH suppression (with adrenal weight reduction as a related measure) rather than 'adrenal insufficiency,' but the mechanism-identity the claim attributes is stated. (LLM, conf=0.85)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mice with a specific GR-deletion in the forebrain show HPA axis hyperactivity; basal cortisol is increased, as well as post-stress cortisol and ACTH levels [57].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Partly supportedcites [57] Arnett M.G. Muglia L.M. Laryea G. Muglia L.J. Genetic approaches to hypothalamic-pituitary-adrenal axis regulation Neuropsychopharmacology 2016 41 245 260 10.1038/npp.2015.215 26189452 PMC4677126 sourceExperimental — accuracy not yet measured
The “Forebrain GR deletion” section reports HPA-axis hyperactivity and increased basal and post-stress cort and post-stress ACTH in male forebrain-GR-deletion mice. It also says female mice showed no increase in basal or stress-induced cort, so the claim is too broad without the male qualifier. The paper calls the measured hormone “cort,” not cortisol. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moved to clinical practice, this model helps to understand that, in adrenal insufficiency, loss of GC feedback, by itself, can increase POMC gene expression in the pituitary (suggesting that CRH is not absolutely required for changes in POMC expression in response to absolute GC deficiency), but CRH action is essential to guarantee the increase of ACTH secretion.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Supportedcites [59] Muglia L.J. Jacobson L. Luedke C. Vogt S.K. Schaefer M.L. Dikkes P. Fukuda S. Sakai Y. Suda T. Majzoub J.A. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency J. Clin. Investig. 2000 105 1269 1277 10.1172/JCI5250 10792002 PMC315436 source
The Discussion states that POMC mRNA increased after adrenalectomy in CRH-deficient mice and explicitly concludes that CRH is not absolutely required for changes in POMC expression in response to absolute glucocorticoid deficiency. The Introduction likewise says loss of glucocorticoid feedback can increase pituitary POMC gene expression without CRH. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
146 more claims · 15 with their cited sources checked
Create a free account to see all 211 claims and to verify the 175 references still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 52
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is potentially linked to its pharmacokinetics (long half-life of 14.4 hours) and pharmacodynamics (binding affinity to the glucocorticoid receptors 18 times that of dexamethasone) (112).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.3. Clinical Consequence: Tertiary Hypoadrenalism and Adrenal Crisis
“the risk of suppressed adrenal function after a seven-day prednisone treatment is increased in subjects who have a low cortisol level after a dexamethasone suppression test [84].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > References
“84. Neidert S. Schuetz P. Mueller B. Christ-Crain M. Dexamethasone suppression test predicts later development of an impaired adrenal function after a 14-day course of prednisone in healthy volunteers”
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 2×
“Named for their effect on carbohydrate metabolism, glucocorticoids (GCs) regulate different cellular functions as homeostasis, metabolism, development, cognition, and inflammation [1].”
BackgroundThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 3×
“StAR protein, in turn, mediates the translocation of cholesterol to the inner mitochondrial membrane, where the first steroidogenic enzyme is located [18].”
BackgroundMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · cited 1×
“Unfortunately, their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
BackgroundImmune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response
Herman, J. P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J., & Myers, B. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150015 · Cited by 1,819
Corticosteroid inhibition of acth secretion
KELLER-WOOD, M. E., & DALLMAN, M. F. (1984) · Endocrine Reviews · doi:10.1210/edrv-5-1-1 · Cited by 1,219
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol
Van Cauter, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2468 · Cited by 951 · cited 1×
“No difference in physiological cortisol secretion is related to weight or gender [21].”
Background11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887 · cited 1×
“MR expression shows a restricted tissue distribution, with high expression in classical aldosterone target organs, such as kidney, colon, salivary glands, and specific brain regions, and more modest expression in heart, vascular tissues, adipocytes, and specific immune cell populations [52].”
BackgroundKarst, H., Berger, S., Turiault, M., Tronche, F., Schütz, G., & Joëls, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507572102 · Cited by 774 · cited 2×
“However, the literature on the mechanism of rapid GC inhibition of HPA activity is confusing: in rats, there is in vivo evidence that this involves a MR-mediated process [63], but ex vivo studies suggest no MR involvement [66].”
BackgroundRamamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692 · cited 1×
“The discovery that there are multiple GR isoforms generated by alternative splicing [90] leads to understanding the molecular basis for this different sensitivity to GC [91].”
BackgroundThe neuronal mineralocorticoid eeceptor as a mediator of glucocorticoid response
Arriza, J. L., Simerly, R. B., Swanson, L. W., & Evans, R. M. (1988) · Neuron · doi:10.1016/0896-6273(88)90136-5 · Cited by 591
Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system
Whitnall, M. H. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90035-q · Cited by 582 · cited 1×
“This is probably due to the suppressive effects of aldosterone, to the increased sensitivity to low level GC concentrations or to the normal regulation of these endpoints by low GC levels [71].”
BackgroundOster, H., Damerow, S., Kiessling, S., Jakubcakova, V., Abraham, D., Tian, J., Hoffmann, M. W., & Eichele, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.07.002 · Cited by 528 · cited 1×
“The adrenal gland also contains circadian clock genes, expressed in the zona glomerulosa and zona fasciculata, and regulated by the splanchnic nerve, that establish specific time intervals during which the adrenal cells are most responsive to ACTH stimulation [31].”
BackgroundSchäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466 · cited 1×
“This is probably because adrenal insufficiency can develop with the same mechanism, mediating the “therapeutic” anti-inflammatory effects of these compounds [36].”
BackgroundDifferences in Corticosterone and Dexamethasone Binding to Rat Brain and Pituitary1
DE KLOET, R., WALLACH, G., & McEWEN, B. S. (1975) · Endocrinology · doi:10.1210/endo-96-3-598 · Cited by 453 · cited 1×
“Although some MRs are present in the anterior pituitary, studies indicate that GR-mediated effects are predominant in the pituitary [54], while inhibition of the brain–pituitary unit depends mainly from MRs [55,56].”
BackgroundHormonal regulation of hepatic glucose production in health and disease
Lin, H. V., & Accili, D. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.003 · Cited by 429 · cited 2×
“The increase in cortisol secretion starting in the early morning helps to maintain plasma glucose (via increases in hepatic gluconeogenesis) until awakening when the overnight fast is broken [20].”
BackgroundSchlaghecke, R., Kornely, E., Santen, R. T., & Ridderskamp, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260403 · Cited by 381
Corticosteroid injections for osteoarthritis of the knee: Meta-analysis
Arroll, B., & Goodyear-Smith, F. (2004) · BMJ · doi:10.1136/bmj.38039.573970.7c · Cited by 348 · cited 1×
“The true incidence of tertiary hypoadrenalism with the use of these local compounds is largely unknown and based mainly on case reports while guidelines concerning the frequency and interval between injections are lacking [43].”
BackgroundBusillo, J. M., & Cidlowski, J. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.005 · Cited by 339
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 1×
“Daily cortisol rhythm in healthy volunteers [23].”
Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319 · cited 1×
“79% on long-term courses, longer than three months) [33,34].”
BackgroundCircadian rhythm of adrenal glucocorticoid: its regulation and clinical implications
Chung, S., Son, G. H., & Kim, K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.003 · Cited by 305 · cited 9×
“As well as SCN, important excitatory inputs for CRH secretion also originate from the amygdala and the raphe nuclei (sites of origin of the serotonergic projections) and from the locus coeruleus of the brain stems, where ascending noradrenergic fibers originate [25].”
BackgroundInfluentialSuppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment
Henzen, C., Suter, A., Lerch, E., Urbinelli, R., Schorno, X. H., & Briner, V. A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06290-x · Cited by 290 · cited 1×
“In fact, there is a clear evidence that patients are at lower risk for adrenal insufficiency if they take GCs on alternate days from the outset or if they can convert to alternate-day therapy before the development of HPA axis suppression [83].”
BackgroundCrosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects
Kassel, O., & Herrlich, P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.003 · Cited by 277 · cited 3×
“GRE-bound GR recruits multiple transcriptional co-activator complexes, whi h stimulate transcription [61].”
BackgroundInfluentialSystemic effects of intra-articular corticosteroids
Habib, G. S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1135-x · Cited by 273 · cited 2×
“Recovery of the HPA axis to baseline normally requires 1–4 weeks, but can be longer in consideration of the dose and frequency of injections [41].”
BackgroundCircadian rhythms of melatonin and cortisol in aging
Sharma, M., Palacios-Bois, J., Schwartz, G., Iskandar, H., Thakur, M., Quirion, R., & Nair, N. P. V. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90178-9 · Cited by 260 · cited 2×
“This suggests both weakened responsiveness of the circadian system in the elderly to the day-night cycle and also a different relationship between the pacemakers driving melatonin and cortisol circadian secretion [22].”
BackgroundClinical Features Associated with Glucocorticoid Receptor Polymorphisms: An Overview
Manenschijn, L., van den Akker, E. L. T., Lamberts, S. W. J., & van Rossum, E. F. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05013.x · Cited by 249
Hypothalamic-pituitary-adrenocortical axis regulation
Jacobson, L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.003 · Cited by 248 · cited 3×
“In physiological conditions, cortisol can both directly inhibit POMC transcription and ACTH secretion and also indirectly inhibit ACTH secretion by decreasing CRH secretion [50] which, as mentioned before, represents an important regulator of ACTH release.”
BackgroundInfluentialClock genes, oscillators, and cellular networks in the suprachiasmatic nuclei
Hastings, M. H., & Herzog, E. D. (2004) · Journal of Biological Rhythms · doi:10.1177/0748730404268786 · Cited by 246 · cited 1×
“The SCN is composed of around 10,000 neurons located above the optic chiasma and it is divided into two regions: a ventral “core” region receiving information from the retina and brain stem and a dorsal “shell” region, which represents a primary pacemaker driving behavioural and other rhythms [26].”
BackgroundReview: Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy
Chan, S., & Debono, M. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380214 · Cited by 243 · cited 12×
“As well as SCN, important excitatory inputs for CRH secretion also originate from the amygdala and the raphe nuclei (sites of origin of the serotonergic projections) and from the locus coeruleus of the brain stems, where ascending noradrenergic fibers originate [25].”
BackgroundInfluentialSpencer, R. L., Young, E. A., Choo, P. H., & McEwen, B. S. (1990) · Brain Research · doi:10.1016/0006-8993(90)90433-c · Cited by 235 · cited 3×
“Then, GRs in the brain, and especially in the hippocampus, are more sensitive to circulating levels of GCs than the pituitary [51].”
BackgroundExogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224 · cited 1×
“Indeed, the so called “iatrogenic Cushing’s syndrome” related to exogenous administration of GCs, represents the most frequent cause of hypercortisolism [10,11].”
BackgroundGrossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510397 · Cited by 212 · cited 8×
“Furthermore, it has been confirmed that aldosterone (which is often described as possessing no GC activity) shows GR-mediated transactivation at concentrations relative to cortisol that are not even reached neither in primary hyperaldosteronism nor in replacement therapy with fludrocortisone [65].”
BackgroundMethodInfluentialIntra-Articular Corticosteroids: Guide to Selection and Indications for Use
Caldwell, J. R. (1996) · Drugs · doi:10.2165/00003495-199652040-00004 · Cited by 208
Glucocorticoid-induced adrenal insufficiency
Krasner, A. S. (1999) · JAMA · doi:10.1001/jama.282.7.671 · Cited by 197 · cited 1×
“Duration and cumulative doses of GC treatment are also useful in defining HPA suppression [82], which is unlikely if the treatment has been performed for less than three weeks (any dose) or with an alternate-day prednisone at a dose of less than 10 mg.”
BackgroundSystemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review
Joseph, R. M., Hunter, A. L., Ray, D. W., & Dixon, W. G. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.03.001 · Cited by 179 · cited 4×
“The results from a recent sy tematic r iew show that hypoadrenalism pe sists in 15% of patient retested thr e years after GC withdr wal [17].”
BackgroundMethodInfluentialPituitary adrenal recovery following short-term suppression with corticosteroids
Streck, W. F., & Lockwood, D. H. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90444-3 · Cited by 178 · cited 2×
“Adrenal gland recovery time c n be short (few days) [15], or as long as several weeks [16] or even ore.”
BackgroundGlucocorticoid inhibition of neurohypophysial vasopressin secretion
Raff, H. (1987) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1987.252.4.r635 · Cited by 160 · cited 1×
“Posterior pituitary AVP is also responsive to GC levels in dogs and humans [69].”
BackgroundDiederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., & Bähr, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020970 · Cited by 154
DALLMAN, M. F., LEVIN, N., CASCIO, C. S., AKANA, S. F., JACOBSON, L., & KUHN, R. W. (1989) · Endocrinology · doi:10.1210/endo-124-6-2844 · Cited by 153
Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself
Dinsen, S., Baslund, B., Klose, M., Rasmussen, A. K., Friis-Hansen, L., Hilsted, L., & Feldt-Rasmussen, U. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.05.014 · Cited by 148
Raff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141 · cited 4×
“Moreover, also a variety of transcription factors can be involved in these mechanisms [29].”
BackgroundInfluentialSingle nucleotide polymorphisms related to hpa axis reactivity
DeRijk, R. H. (2009) · NeuroImmunoModulation · doi:10.1159/000216192 · Cited by 140 · cited 1×
“Several single nucleotide polymorphisms (SNPs), occurring with high frequency and involving GABA receptors, opioid receptors, α2-adrenergic receptors, serotonin transporter, catechol O-methyltransferase, MR, and GR have been associated with the changes in HPA axis reactivity [86].”
BackgroundTempark, T., Phatarakijnirund, V., Chatproedprai, S., Watcharasindhu, S., Supornsilchai, V., & Wananukul, S. (2010) · Endocrine · doi:10.1007/s12020-010-9393-6 · Cited by 131 · cited 4×
“Clobetasol propionate is one of the most potent topical GCs: its potency is estimated to be 600 times higher than hydrocortisone [45] and the use of 2 g/day of 0.”
BackgroundInfluentialAdcock, I. M., & Mumby, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_98 · Cited by 131
Glutamate immunoreactivity in terminals of the retinohypothalamic tract of the brown norwegian rat
de Vries, M. J., Cardozo, B. N., van der Want, J., de Wolf, A., & Meijer, J. H. (1993) · Brain Research · doi:10.1016/0006-8993(93)91665-f · Cited by 128 · cited 1×
“Photic environmental cues are perceived by melanopsin-containing retinal ganglion cells that transfer their outputs to the SCN via the retinohypothalamic tract, whose main neurotransmitter is glutamate [27].”
BackgroundIncidence of adrenal crisis in patients with adrenal insufficiency
Smans, L. C. C. J., Van der Valk, E. S., Hermus, A. R. M. M., & Zelissen, P. M. J. (2016) · Clinical Endocrinology · doi:10.1111/cen.12865 · Cited by 127 · cited 2×
“Even if data about the clinical impact of these medications are limited, about 6% of hospitalized patients may have a GC-induced adrenal insufficiency [35].”
BackgroundSCHULTE, H. M., CHROUSOS, G. P., AVGERINOS, P., OLDFIELD, E. H., GOLD, P. W., CUTLER, G. B., & LORIAUX, D. L. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-6-1064 · Cited by 122 · cited 1×
“The normal ACTH responses to CRH stimulation test in patients being withdrawn from GC treatment further confirms that the suppression is likely due to an ongoing deficit in CRH—rather than in ACTH secretion [60].”
BackgroundThe Role of Mineralocorticoid Receptors in Hypothalamic-Pituitary-Adrenal Axis Regulation in Humans1
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5077 · Cited by 112 · cited 12×
“The effects of synthetic GCs are mediated by their binding to GRs and MRs. HPA axis function is based on the well-known negative feedback mechanism, which seems to involve in particular GRs mainly localized in the pituitary.”
BackgroundInfluentialRussell, G. M., Henley, D. E., Leendertz, J., Douthwaite, J. A., Wood, S. A., Stevens, A., Woltersdorf, W. W., Peeters, B. W. M. M., Ruigt, G. S. F., White, A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5332-09.2010 · Cited by 111 · cited 1×
“This fast feedback inhibition is mainly GR dependent, is independent from CRH drive, occurs predominately in the anterior pituitary and only blocks the regulated pathway of ACTH release [67].”
BackgroundGenetic approaches to hypothalamic-pituitary-adrenal axis regulation
Arnett, M. G., Muglia, L. M., Laryea, G., & Muglia, L. J. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.215 · Cited by 105 · cited 2×
“On the other hand, MR-deletion in the forebrain causes upregulation of GR expression in the hippocampus, but no effect in basic synaptic transmission or in circadian or post-stress cortisol concentrations [57].”
BackgroundTURPEINEN, M., SALO, O. P., & LEISTI, S. (1986) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1986.tb06242.x · Cited by 104 · cited 2×
“Old data collected in 1986 showed a positive relationship between adrenal suppression and the increase in serum cortisol level following the use of topical 1% hydrocortisone; furthermore, the HPA axis suppression was longer in infant compared with older children, because infants have a larger ratio body surface area t…”
BackgroundMonitoring glucocorticoid therapy: a pharmacokinetic approach
Hill, M. R., Szefler, S. J., Ball, B. D., Bartoszek, M., & Brenner, A. M. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.167 · Cited by 103 · cited 1×
“Other findings included different absorption of GCs and reduced clearance with older age [78].”
BackgroundDAYANITHI, G., & ANTONI, F. A. (1989) · Endocrinology · doi:10.1210/endo-125-1-308 · Cited by 103 · cited 10×
“The effects of synthetic GCs are mediated by their binding to GRs and MRs. HPA axis function is based on the well-known negative feedback mechanism, which seems to involve in particular GRs mainly localized in the pituitary.”
BackgroundInfluentialComparison of Inhaled Corticosteroids: An Update
Kelly, H. W. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l546 · Cited by 101 · cited 1×
“Inhaled synthetic glucocorticoids [12,39].”
Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease
Koper, J. W., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · Steroids · doi:10.1016/j.steroids.2014.07.015 · Cited by 97 · cited 1×
“The discovery that there are multiple GR isoforms generated by alternative splicing [90] leads to understanding the molecular basis for this different sensitivity to GC [91].”
BackgroundThe Role of Mineralocorticoid Receptors in Hypothalamic-Pituitary-Adrenal Axis Regulation in Humans
Young, E. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3339 · Cited by 95
Corticosterone acts on the brain to inhibit adrenalectomy-induced adrenocorticotropin secretion
LEVIN, N., SHINSAKO, J., & DALLMAN, M. F. (1988) · Endocrinology · doi:10.1210/endo-122-2-694 · Cited by 87 · cited 1×
“In these models without hypophysiotrophic input, supraphysiologic GC levels are required to inhibit exogenous CRH-induced ACTH secretion [58].”
BackgroundMouri, T., Itoi, K., Takahashi, K., Suda, T., Murakami, O., Yoshinaga, K., Andoh, N., Ohtani, H., Masuda, T., & Sasano, N. (2008) · Neuroendocrinology · doi:10.1159/000126339 · Cited by 85 · cited 1×
“Basal concentration of AVP mRNA in the CRH KO mice are elevated, accordingly with other studies in rats which demonstrated an elevation in parvocellular CRH mRNA with reduction of plasma corticosterone concentrations [70].”
ResultApparent mineralocorticoid excess
Funder, J. W. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.010 · Cited by 83
Muglia, L. J., Jacobson, L., Luedke, C., Vogt, S. K., Schaefer, M. L., Dikkes, P., Fukuda, S., Sakai, Y., Suda, T., & Majzoub, J. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci5250 · Cited by 80 · cited 5×
“Adrenalectomy in CRH KO mice determines a further increase in hypothalamic AVP mRNA, demonstrating their ability to respond to the absolute GC deficiency in a manner similar to that of wild-type mice [59].”
BackgroundResultInfluentialIatrogenic cushing’s syndrome and topical steroid therapy: Case series and review of the literature
Decani, S., Federighi, V., Baruzzi, E., Sardella, A., & Lodi, G. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2012.755252 · Cited by 79 · cited 2×
“Topical synthetic glucocorticoids (potency according to European Corticosteroids Classification) [48].”
BackgroundGlucocorticoid therapy and ocular hypertension
Dibas, A., & Yorio, T. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.06.018 · Cited by 75 · cited 1×
“Unfortunately, their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
BackgroundSaberi, P., Phengrasamy, T., & Nguyen, D. (2013) · HIV Medicine · doi:10.1111/hiv.12039 · Cited by 73 · cited 2×
“inhaled GCs [76], but also, with the same mechanisms, in patients treated with intra-articular [42] or topical GCs who were taking protease inhibitors, itraconazole, macrolides, and diltiazem [45].”
BackgroundWithdrawal from glucocorticosteroid therapy: Clinical practice recommendations
Alves, C., Robazzi, T. C. V., & Mendonça, M. (2008) · Jornal de Pediatria · doi:10.2223/jped.1773 · Cited by 72 · cited 1×
“Furthermore, systemic therapy is more likely to suppress the HPA axis, even if other routes of administration (inhalation, topical, intra-ocular) cause HPA axis suppression depending on the bioavailability of the drug [80].”
BackgroundGlucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Russell, G. M., Kalafatakis, K., & Lightman, S. L. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12247 · Cited by 68
Atkinson, H. C., Wood, S. A., Castrique, E. S., Kershaw, Y. M., Wiles, C. C. R., & Lightman, S. L. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00721.2007 · Cited by 68 · cited 3×
“However, the literature on the mechanism of rapid GC inhibition of HPA activity is confusing: in rats, there is in vivo evidence that this involves a MR-mediated process [63], but ex vivo studies suggest no MR involvement [66].”
BackgroundJamilloux, Y., Liozon, E., Pugnet, G., Nadalon, S., Heang Ly, K., Dumonteil, S., Gondran, G., Fauchais, A.-L., & Vidal, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068713 · Cited by 59 · cited 1×
“It is not clear whether or not the dose and the duration of GCs therapy increase the risk of developing adrenal insufficiency: some authors found no relationship between either the dose or duration of therapy and adrenal insufficiency [13], while others found that both cumulative doses and treatment durations are asso…”
BackgroundJohnston, P. C., Lansang, M. C., Chatterjee, S., & Kennedy, L. (2015) · Endocrine · doi:10.1007/s12020-014-0409-5 · Cited by 58 · cited 4×
“inhaled GCs [76], but also, with the same mechanisms, in patients treated with intra-articular [42] or topical GCs who were taking protease inhibitors, itraconazole, macrolides, and diltiazem [45].”
BackgroundMethodInfluentialHigh Risk of Adrenal Insufficiency after a Single Articular Steroid Injection in Athletes
DUCLOS, M., GUINOT, M., COLSY, M., MERLE, F., BAUDOT, C., CORCUFF, J. B., & LEBOUC, Y. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31805468d6 · Cited by 55 · cited 1×
“It is important to underline that a non-recognized adrenal suppression can be extremely dangerous for the juvenile population who may not be aware of the signs and symptoms, as well as for athletes, and for those who participate in extreme sports at risk of trauma, infection, and acute stress [44].”
BackgroundNeurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron
CALOGERO, A. E. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44668.x · Cited by 53 · cited 1×
“Inhibitory inputs on CRH secretion derive from the hippocampus and the locus coeruleus of the midbrain and are mainly mediated by gamma-aminobutyric acid (GABA) and nitric oxide (NO) [28].”
BackgroundDifferential and integral corticosteroid feedback effects on acth secretion in hypoadrenocorticism
Fehm, H. L., Voigt, K. H., Kummer, G., Lang, R., & Pfeiffer, E. F. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109296 · Cited by 51 · cited 1×
“The so-called “fast feedback” is a rapid-non genomic mechanism of action, which has been well documented in rats [63], although there is evidence suggesting a similar mechanism in humans [64].”
BackgroundCentral nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function
Locatelli, V., Bresciani, E., Tamiazzo, L., & Torsello, A. (2010) · Endocrine development · doi:10.1159/000262533 · Cited by 48 · cited 2×
“As well as SCN, important excitatory inputs for CRH secretion also originate from the amygdala and the raphe nuclei (sites of origin of the serotonergic projections) and from the locus coeruleus of the brain stems, where ascending noradrenergic fibers originate [25].”
BackgroundGulliver, T., Morton, R., & Eid, N. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709030-00007 · Cited by 47 · cited 1×
“However, this is not fully true: in fact, after inhalation, the amount that reaches the lungs is absorbed into the bloodstream and, in most cases, it is not metabolized to biologically-inactive compounds by the respiratory tract [37].”
BackgroundMolecular genetics of the acth and melanocyte-stimulating hormone receptors
Cone, R. D., & Mountjoy, K. G. (1993) · Trends in Endocrinology & Metabolism · doi:10.1016/1043-2760(93)90129-3 · Cited by 45 · cited 1×
“ACTH acts on adrenal glands to stimulate cortisol release via melanocyte type-2 receptor (MC2R) expressed on the zona fasciculata and zona reticularis [30].”
BackgroundKelly, A., Nelson, K., Goodwin, M., & McCluggage, J. (1972) · BMJ · doi:10.1136/bmj.4.5832.114-a · Cited by 42
Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man.
Assandri, A., Buniva, G., Martinelli, E., Perazzi, A., & ZERILLI, L. F. (1984) · PubMed · Cited by 41
Song, Q.-Q., Xie, W.-Y., Tang, Y.-J., Zhang, J., & Liu, J. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0151 · Cited by 40 · cited 1×
“The underlying mechanisms of action can be different, ranging from pharmacokinetic and pharmacodynamic properties of the used drugs to genetic predisposition [85].”
BackgroundDescription des prescriptions de corticothérapies orales en population générale
Fardet, L., Petersen, I., & Nazareth, I. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.02.022 · Cited by 31
The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review
Bazsó, A., Szappanos, Á., Patócs, A., Poór, G., Shoenfeld, Y., & Kiss, E. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.007 · Cited by 28
Kowalski, M. L., Wojciechowski, P., Dziewonska, M., & Rys, P. (2016) · Allergy and Asthma Proceedings · doi:10.2500/aap.2016.37.3912 · Cited by 24 · cited 1×
“However, although ciclesonide does not affect cortisol levels, this appears to be due to its unique pharmacokinetic properties rather than the use of a novel formulation [38].”
BackgroundParagliola, R. M., & Corsello, S. M. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.17.02701-8 · Cited by 23 · cited 3×
“The choice of the most appropriate test for the assessment of HPA axis alterations remains largely debated and, for each test, different cut-offs have been reported with different degrees of sensitivity and specificity [24].”
BackgroundInfluentialSelf-citationSong, Y., Schroeder, J. R., & Bush, L. M. (2014) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957413488187 · Cited by 22 · cited 1×
“Several case reports involving HIV-infected patients treated with the concomitant use HIV protease inhibitor ritonavir (RTV) and triamcinolone have been reported [75].”
BackgroundSecondary adrenal insufficiency: Where is it hidden and what does it look like?
Guaraldi, F., Karamouzis, I., Berardelli, R., D'Angelo, V., Rampino, A., Zichi, C., Ghigo, E., & Giordano, R. (2016) · Frontiers of hormone research · doi:10.1159/000443915 · Cited by 22 · cited 1×
“Accordingly to the literature [81], in patients who have received a GC dose comparable with more than 20 mg of prednisone/day for more than three weeks, HPA suppression is “likely”.”
BackgroundSyndromes de Cushing : physiopathologie, étiologie et principes thérapeutiques
Chabre, O. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.02.001 · Cited by 21
Fifty years ago: The quest for steroid hormone receptors
Rousseau, G. G. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.05.005 · Cited by 18 · cited 1×
“Indeed, cortisol, like other steroid hormones, interact with cytoplasmatic receptors which cause changes in gene transcription and translation [49].”
BackgroundHypothalamic-pituitary-adrenal axis recovery following prolonged prednisolone therapy in infants
Mendoza-Cruz, A. C., Wargon, O., Adams, S., Tran, H., & Verge, C. F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2649 · Cited by 16 · cited 2×
“Adrenal gland recovery time c n be short (few days) [15], or as long as several weeks [16] or even ore.”
BackgroundWassner, C., Maiti, S., Kodroff, K., & Cohen, H. (2017) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957417729748 · Cited by 15
Baker, A. C., Chew, V. W., Green, T. L., Tung, K., Lim, D., Cho, K., & Greenhalgh, D. G. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2012.12.027 · Cited by 14 · cited 1×
“The presence of either SNP A214G or T962C results in a decreased response after stimulation with both hydrocortisone and dexamethasone [89].”
BackgroundNeidert, S., Schuetz, P., Mueller, B., & Christ-Crain, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0930 · Cited by 13 · cited 1×
“It has been demonstrated that the risk of suppressed adrenal function after a seven-day prednisone treatment is increased in subjects who have a low cortisol level after a dexamethasone suppression test [84].”
BackgroundA novel human glucocorticoid receptor SNP results in increased transactivation potential
Green, T. L., Tung, K. L., Lim, D., Leventhal, S. M., Cho, K., & Greenhalgh, D. G. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.12.003 · Cited by 12 · cited 1×
“On the other hand, the SNP A829G, was found to increase the transactivation potential of the GR [88].”
BackgroundJamilloux, Y., Liozon, E., Pugnet, G., Nadalon, S., Heang Ly, K., Dumonteil, S., Gondran, G., Fauchais, A.-L., & Vidal, E. (2013) · PLoS ONE · doi:10.1371/annotation/66da2350-2981-489a-932d-3a456c8d0e49 · Cited by 5
Cited by
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Chronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
“A brief summary of pharmacodynamics for select glucocorticoids are provided in Table 3 (adapted from [75]).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Role of the Hypothalamic–Pituitary–Adrenal Axis in Health and Disease
DeMorrow, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040986 · Cited by 119
“[14] Treatment with Synthetic Glucocorticoids and the Hypothalamus–Pituitary–Adrenal Axis Synthetic glucocorticoid, tertiary hypoadrenalism, iatrogenic Cushing’s syndrome Review”
MethodBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Metadata
- Authors
- Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Corsello, Salvatore Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-10-20
- Volume
- 18
- Issue
- 10
- Pages
- 2201
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5666882
- OpenAlex
- W2765223108
- Semantic Scholar
- ad19ea2188368acba719dc110c72abdf5db33d87
- Cited by
- 181
- References
- 93
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 23 · 2023: 23 · 2022: 25 · 2021: 34 · 2020: 16 · 2019: 23 · 2018: 10 · 2017: 1
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- synthetic glucocorticoids, hypothalamic-pituitary-adrenal axis, Cushing's syndrome, tertiary adrenal insufficiency, corticotropin-releasing factor, ACTH, glucocorticoid withdrawal
- MeSH terms
- Adrenocorticotropic Hormone, Animals, Corticotropin-Releasing Hormone, Cushing Syndrome, Glucocorticoids, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Feedback, Physiological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.